BDR Pharma launches Nintenib to treat idiopathic pulmonary fibrosis in India

BDR Pharmaceutical has announced the launch of 100mg and 150 mg nintedanib under the brand name Nintenib for the treatment of idiopathic pulmonary fibrosis (IPF). Nintenib is priced at Rs. 750 (100 mg) and Rs. 900 (150 mg) for a pack of 10 tabs.
Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosi

The median survival in IPF patients is 2.5 to 3.5 years. Nintedanib received Drugs Controller General of India (DCGI) approval after showing a significant slowdown in the disease progression in patients with pulmonary fibrosis by reducing the rate of decline in forced vital capacity (FVC) in patients with IPF and mild or moderate lung function impairment.

Currently, there are two clinical trials being conducted to study the safety and efficacy of nintedanib for the treatment of moderately to critically ill COVID-19 patients suffering from IPF.

Dharmesh Shah, CMD, BDR Pharmaceuticals said, “We are thrilled to innovate and work towards introducing newer, effective and affordable treatment options for patients. We are proud to launch the generic version of the drug for lung fibrosis in India especially during a time when there is an ardent need of the medicine for COVID-19 patients. We are happy to lend our hand in any way to ensure the community is better prepared during this pandemic. With the launch of nintedanib, we are on the verge of changing the therapeutic dynamics in the segment of tyrosine kinase inhibitors”.

Nintedanib is a small molecule tyrosine kinase inhibitor, targeting vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) involved in signaling pathways which lead to its use in pulmonary fibrosis. It has also shown significant efficacy in the management of non-small cell carcinoma of the lung as well as systemic sclerosis.

BDR is recognized as a niche player in manufacturing of pharmaceutical APIs and for the renowned new age formulations. BDR Group of companies has grown steadily in the pharmaceutical Industry over the last 15 years, in both domestic and international arenas. The group is complemented majorly by its two companies - BDR Pharmaceuticals International Pvt Ltd and BDR Life Sciences Pvt. Ltd, each one having stamped its own supremacy in respective fields, i.e. API and formulation manufacturing, respectively.

BDR Group focuses on development in 6 specialized therapeutic segments, viz. oncology, critical care, gynaecology & neurology, dermatology and women’s health which are its dream segment.


Source:http://www.pharmabiz.com/NewsDetails.aspx?aid=132891&sid=2

Comments

Post a Comment

Popular posts from this blog

EMA validates Incyte’s MAA for retifanlimab to treat metastatic squamous cell anal carcinoma

Incyte, global biopharmaceutical company, announced the validation of the Company’s Marketing Authorization Application (MAA) for retifanlimab, an intravenous PD-1 inhibitor, as a potential treatment for adult patients with locally advanced or metastatic squamous cell anal carcinoma (SCAC) who have progressed on, or who are intolerant of, platinum-based chemotherapy. The European Medicines Agency’s (EMA) validation of the MAA confirms that the submission is sufficiently complete to begin the formal review process. “While the incidence of SCAC is increasing in Europe, treatment options for advanced disease are limited in their effectiveness, and there are no approved options once patients have progressed on standard therapy,” said Lance Leopold, M.D., Group vice president, Immuno-Oncology Clinical Development, Incyte. “The EMA validation of the MAA for retifanlimab – which follows the recent US Food & Drug Administration acceptance of our Biologics License Application for Priority R...
Read more

Tumour-targeting drug paves way for bone cancer treatment

 The treatment of osteosarcoma, the most common tumour of bone, is challenging, but a new study is offering hope to the patients with this disease. The study led by The University of  Texas MD Anderson Cancer Centre  found that a drug, known as bone metastasis-targeting peptidomimetic (BMTP-11), has potential as a new therapeutic strategy for this devastating illness. Results from the preclinical study looked at BMTP-11 alone and in combination with the chemotherapy agent gemcitabine. Although osteosarcoma is a relatively rare cancer, it is a leading disease-related cause of death in children and young adults ages 10 to 20. However, over the last 25 years, the five-year survival rate has remained unchanged, and the treatment options for these patients are few. In addition, the side effects of available treatment options often are significant and cumulative, and may cause other health problems and damage to major organs. "What's novel about this treatment is that...
Read more

Merck’s Keytruda plus platinum- and fluoropyrimidine-based chemotherapy receives US FDA nod to treat certain patients with locally advanced/metastatic esophageal or GEJ carcinoma

Merck, known as MSD outside the United States and Canada, announced that the US Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. The approval is based on results from the phase 3 KEYNOTE-590 trial, which demonstrated significant improvements in overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) for Keytruda plus fluorouracil (FU) and cisplatin versus FU and cisplatin alone, regardless of histology or PD-L1 expression status. For OS and PFS, Keytruda plus FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; p<0.0001) and reduced the risk of disease progression or death...
Read more